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Abstract: The regulator of G-protein signaling (RGS) modulates the functioning of heterotrimeric G protein. RGS9-2  
is highly expressed in the striatum and plays a role in modulating dopaminergic receptor-mediated signaling cascades. 
Previous studies suggested that the RGS9 gene might contribute to the susceptibility to psychotic diseases. Therefore, we 
investigated the association between the RGS9 gene and two related dopamine psychoses, schizophrenia and metham-
phetamine use disorders. The subjects comprised 487 patients of schizophrenia and 464 age- and sex-matched healthy 
controls and 220 patients of methamphetamine use disorder and 289 controls. We genotyped two nonsynonymous poly-
morphisms, rs12452285 (Leu225Ser) and rs34797451 (His498Arg), of the RGS9 gene. Rs34797451 showed monomor-
phism in the present Japanese population, but rs12452285 showed polymorphism. There were no significant differences in 
genotypic or allelic distributions of rs12452285 between patients with schizophrenia and the corresponding control or  
between patients with methamphetamine use disorder and the corresponding control. We also analyzed the clinical   
features of methamphetamine use disorder. We found a significant association in allelic distribution with the phenotypes 
of age at first consumption (p=0.047). The present study suggested that the RGS9 gene is unlikely to play a major role  
in schizophrenia and methamphetamine dependence liability and/or the development of methamphetamine induced   
psychosis, at least in a Japanese population. 
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INTRODUCTION 
  Human and animal studies suggest that the D2-like do-
pamine receptors play a central role in the development of 
substance dependence and substance-induced psychotic dis-
orders due to consumption of a diverse class of drugs, e.g., 
alcohol, nicotine, opioids, cannabinoids, cocaine, and am-
phetamines, and also of endogenous psychosis of schizo-
phrenia [1-3]. Two animal models of schizophrenia, an am-
phetamine-sensitized rat and the phencyclidine-treated rat, 
showed marked dopamine supersensitivity and an increase in 
the proportion of striatal D2 receptors in the high-affinity 
state [4-7]. These findings indicate that the dopamine system 
is involved in the neural mechanisms of psychiatric disor-
ders, substance use disorders, and schizophrenia. 
  The activity of the dopamine receptors is regulated by 
intricate mechanisms including the heterotrimeric G protein 
system. The regulator of G-protein signaling (RGS) modu-
lates the functioning of heterotrimeric G protein in part by  
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stimulating the GTPase activity of the G protein subunits [8, 
9]. RGS9 is a member of the RGS family, and the RGS9 
gene gives rise to two products, RGS9-1 and RGS9-2, via 
alternative splicing [10, 11]. RGS9-1 is expressed in the   
retina, and RGS9-2 is highly expressed in the striatum and 
plays a role in modulating dopaminergic-mediated signaling 
cascades [12, 13]. Previous studies showed that the expres-
sion of RGS9-2 in the postmortem brain of schizophrenia 
patients was lower than that of controls [14, 15]. RGS9 
knockout mice showed supersensitivity to dopamine and 
marked elevation in the proportion of D2 high-affinity recep-
tors [13]. These findings suggest that the RGS9 gene varia-
tion contributes to the sensitivity of D2 receptors in the brain 
and to development of psychotic disorders. 
  It is well known that consumption of methamphetamine, 
an indirect dopamine agonist, produces psychosis at a high 
rate. The symptoms of methamphetamine-induced psychosis 
are similar to those of schizophrenia, and the diseases show a 
cognate course of illness. Thus, it seemed that metham-
phetamine use disorder and schizophrenia share in part the 
mechanisms of their neural pathogenesis. Based on the above 
rationale, we investigated the association between the RGS9 
gene and methamphetamine use disorder or schizophrenia in 
a Japanese population. Association between the Regulator of G-protein Signaling 9 Gene  Current Neuropharmacology, 2011, Vol. 9, No. 1    191 
METHODS 
Subjects 
  The subjects comprised 220 unrelated patients with 
methamphetamine dependence (175 males and 45 females, 
average age 37.0 ± 11.8 years) who met the ICD-10-DCR 
criteria (F15.2), 486 schizophrenic patients (247 males and 
240 females, average age 50.5 ± 12.8 years) who met F20, 
and two sets of corresponding age-, sex-, and geographical 
origin-matched healthy controls, 289 control subjects (225 
males and 64 females, average age 37.1 ± 12.8 years) and 
464 control subjects (225 males and 239 females, average 
age 51.3 ± 14.3 years) . Two hundred and eighteen of   
the patients with methamphetamine dependence have or   
had comorbid methamphetamine psychosis (F15.5). Among 
the schizophrenic patients, 221 were the paranoid subtype 
and 239 were the hebephrenic subtype. Diagnosis of meth-
amphetamine use disorder and schizophrenia and determina-
tion of subtype was performed by two trained psychiatrists 
on the basis of all available information. Most of the control 
subjects were medical staff members who had no past history 
or family history of substance dependence or major   
psychotic disorders. All subjects were Japanese, born and 
living in restricted areas of Japan. This study was initiated 
after receiving the approval of the ethical committees of   
the participating institutions. Written informed consent was 
obtained from all participants. 
Clinical Phenotypes 
  Clinical observation has revealed substantial inter-
individual differences in certain phenotypes of metham-
phetamine-taking behavior and psychosis that seem to be 
regulated, at least in part, genetically. The rationale and 
methods of the subgrouping of phenotypes were previously 
described [16]. In brief, the patients with methamphetamine 
dependence and psychosis were divided into five subgroups 
according to the following clinical phenotypes: multisub-
stance-abuse status, age at first consumption of metham-
phetamine, latency to the onset of psychotic symptoms after 
the first consumption of methamphetamine, prognosis of 
psychosis after therapy, and the complication of spontaneous 
relapse to a psychotic state. 
Genotyping 
  Peripheral blood was obtained from the subjects, and the 
genomic DNA was extracted from peripheral leukocytes 
using a standard procedure. We selected two nonsynony-
mous polymorphisms, rs12452285 (Leu225Ser) in exon 12 
and rs34797451 (His498Arg) in exon 18, of the RGS9 gene. 
Genotyping was performed using TaqMan technology on an 
ABI7500 Real Time PCR system (Applied Biosystems, Fos-
ter City, CA, USA). All genotyping was performed in a 
blinded fashion, with the control and case samples mixed 
randomly. 
Statistical Analysis 
  Statistical analysis of association was performed using 
SNPAlyze software (Dynacom Co., Mobara, Chiba, Japan). 
Deviation from Hardy-Weinberg equilibrium and the case-
control study were tested using the 
2 test. The differences 
between subgroups were evaluated on Fisher’s exact test. 
Statistical significance was set at 0.05. 
RESULTS 
  Rs34797451 showed monomorphism in the present Japa-
nese population, but rs12452285 showed polymorphism. 
Accordingly, subsequent analyses were done on rs12452285 
only. The genotype distribution and allele frequencies for the 
polymorphism of patients with methamphetamine use disor-
der and control subjects are shown in Table 1 and those for 
the patients of schizophrenia in Table 2. The genotype distri-
butions of patients and control subjects did not deviate from 
Table 1.  Genotype and Allele Distributution of rs12452285 of the RGS9 Gene with METH Use Disorder and Controls 
                                                            Genotype(%)   P  Allele(%)   P 
rs12452285  N  C/C  C/T  T/T   C T   
Controls 289  266(92.0)  23(8.0)  0(0.0)    555(96.0)  23(4.0)   
Patients 220  200(90.9)  18(8.2)  2(0.9)  0.27  418(95.0)  22(5.0)  0.43 
Table 2.  Genotype and Allele Distribution of rs12452285 of the RGS9 Gene in Patients with Schizophrenia and Controls 
                                                                                     Genotype(%)   P   Allele(%)   P 
rs12452285 N  C/C  C/T  T/T    C  T   
Controls 464  422(91.0)  39(8.4)  3(0.6)    883(95.2)  45(4.8)   
Schizophrenics 487  428(87.9)  57(11.7)  2(0.4)  0.02  913(93.7)  61(6.3)  0.18 
 Paranoid type  221  190(86.0)  30(13.6)  1(0.4)  0.11  410(92.8)  32(7.2)  0.07 
 Hebephrenic type  239  215(90.0)  23(9.6)  1(0.4)  0.81  453(94.8)  25(5.2)  0.76 192    Current Neuropharmacology, 2011, Vol. 9, No. 1  Okahisa et al. 
Hardy-Weinberg equilibrium at the polymorphism. We 
found no significant differences in genotypic or allelic distri-
bution of rs12452285 between methamphetamine use disor-
der and the corresponding controls or between schizophrenia 
and the corresponding controls. 
  To investigate further the roles of the RGS9 gene in the 
pathophysiology of psychosis and drug-taking behaviors, we 
examined the association of the RGS9 gene with several 
clinical phenotypes of methamphetamine dependence and 
psychosis, i.e., the age at first consumption of metham-
phetamine, latency to onset of psychosis after abuse, progno-
sis of psychosis after therapy, spontaneous relapse even 
without reconsumption of methamphetamine, and multiple 
substance abuse status, which show individual variation and 
may in part be regulated genetically. There was a significant 
difference in allelic distribution between the two subgroups 
divided by age of first use of methamphetamine (p=0.047, 
Table  3) but not in genotypic distribution. For the other 
clinical phenotypes, there was no significant association with 
genotypic or allelic distributions of rs12452285 of the RS9 
gene. 
DISCUSSION 
  The present study showed that the RGS9 gene is not as-
sociated with susceptibility to methamphetamine use disor-
der or schizophrenia. There was a significant difference in 
allelic distribution in the phenotype of age at first consump-
tion of methamphetamine (P=0.047), but the significance 
was marginal, and there was no significant difference in its 
genotypic distribution, indicating a necessity for confirma-
tion by replication analyses. 
  It was well known that three different conditions, psy-
chostimulant-induced behavioral sensitization in rodents, 
psychostimulant-induced psychoses in humans, and chronic 
schizophrenia show similar longitudinal alternations, pro-
gressively enhanced susceptibility to abnormal behaviors, 
psychotic state, and relapse [17]. Many studies suggest that 
the susceptibility to dopamine release that developed in the 
striatum and accumbens is the most direct and common 
mechanism for the behavioral sensitization phenomenon in 
rodents after administration of psychostimulants including 
methamphetamine, amphetamine, and cocaine [18-22]. Two 
independent groups found approximately twice as much am-
phetamine-induced dopamine efflux in the striatum of pa-
tients with schizophrenia in comparison to healthy controls 
[23, 24]. These data support a hypothesis that a process of 
endogenous sensitization of dopaminergic systems is in-
volved in the pathogenesis of schizophrenia. 
  There are two splice isoforms of the RGS9 gene. RGS9-1 
is the short splice isoform and expressed in the retina, and 
RGS9-2 is the long splice isoform, which is highly expressed 
in striatum [10, 11]. RGS9-2 was present in a large fraction 
of D2 receptor-containing neurons and co-expression of 
RGS9-2 accelerated D2-mediated channel activation [13]. It 
was revealed that a single injection of amphetamine reduced 
the RGS9 mRNA levels [25]. RGS9 knockout mice showed 
heightened locomotor and rewarding responses to cocaine 
and a marked increase in the proportions of D2
High receptors 
Table 3.  Subgroups of METH Dependence and Psychosis by Clinical Characteristic 
Clinical Phenotype    Genotype(%)   P  Allele(%)   P 
rs12452285  N C/C C/T  T/T    C  T   
Multisubstance abuse 
 Yes  155  141(91.0)  14(9.0)  0(0.0)  0.06  296(95.5)  14(4.5)  0.34 
 No  59  53(89.8)  4(6.8)  2(3.4)    110(93.2)  8(6.8)   
Age at first consumption 
 20 117  103(88.0)  13(11.1)  1(0.9)  0.08  219(93.6)  15(6.4)  0.047 
 >20  101  96(95.0)  4(4.0)  1(1.0)    196(97.0)  6(3.0)   
Latency to onset of psychosis 
 3 years  101  93(92.1)  8(7.9)  0(0.0)  0.33  194(96.0)  8(4.0)  0.36 
 >3 years  92  83(90.2)  7(7.6)  2(2.2)    173(94.0)  11(6.0)   
Prognosis of psychosis 
 Transient   112  104(92.9)  7(6.2)  1(0.9)  0.61  215(96.0)  9(4.0)  0.34 
 Prolonged  90  80(88.9)  9(10.0)  1(1.1)    169(93.9)  11(6.1)   
Spontaneous relapse of psychosis 
 Yes  93  85(91.4)  6(6.5)  2(2.1)  0.21  176(94.6)  10(5.4)  0.75 
 No  117  106(90.6)  11(9.4)  0(0.0)    223(95.3)  11(4.7)   Association between the Regulator of G-protein Signaling 9 Gene  Current Neuropharmacology, 2011, Vol. 9, No. 1    193 
[4, 13]. In particular, RGS9 knockout mice showed condi-
tioned place preference after lower doses of cocaine than the 
wild type [13]. Consistent with the result, overexpression of 
RGS9-2 induced by injection of a herpes simplex virus re-
duced the dopamine sensitivity [13]. The other group re-
ported that mice lacking RGS9 show a 10-fold increase in 
sensitivity to the rewarding effects of morphine [26]. These 
lines of evidence suggest that RGS9 plays an important   
role in substance use disorder by modulating the dopamine 
pathway via D2 receptors. Recently, Seeman et al. reported 
that expression of RGS9-2 was reduced by 22% in the   
hippocampus of humans with schizophrenia [15], and the 
result is consistent with the previous study that reported a 
40% reduction of RGS9 in the prefrontal cortices in schizo-
phrenia [14]. They also found that the expression of RGS9-2 
in the amphetamine-sensitized rat striatum was reduced by 
11% [15]. 
  The RGS9 gene is located on chromosome region 17q21-
25 [11], and the region was implicated in major mental   
illness susceptibility through linkage studies [27-30]. We 
analyzed two SNPs, rs12452285 (Leu225Ser) and rs34797451 
(His498Arg), of the RGS9 gene because these are the only 
two nonsynonymous polymorphisms in the RGS9 gene   
registered in the NCBI SNP database. Recently, Liou et al. 
examined a possible association between the RGS9 gene   
and tardive dyskinesia using seven single nucleotide poly-
morphisms, rs8077696, rs8070231, rs2292593, rs2292592, 
rs9916525, rs1122079 and rs4790953. In haplotype analyses, 
they found a significant association with the haplotype con-
sisting of rs8077696, rs8070231, and rs2292593 of the RGS9 
gene [31]. Tardive dyskinesia is an abnormal involuntary 
movement disorder usually caused by chronic antipsychotic 
treatment, which blocks D2 dopamine receptors and may 
induce subsequent supersensitivity of D2 receptors. There-
fore, it is possible that the haplotype consisting of these 
markers is associated with functional changes in RGS9, and 
a possible candidate for RGS9 analyses for methampheta-
mine use disorder or schizophrenia. 
  In conclusion, this study showed that the RGS9 gene is 
unlikely play a major role in schizophrenia and metham-
phetamine use disorder liability and/or the development of 
methamphetamine induced psychosis, at least in a Japanese 
population.  
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